Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

ABCDE and ugly-duckling assessment of pigmented lesions

Dermatology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull

Synopsis

Assess a pigmented lesion systematically, compare it with the patient’s mole pattern, use the weighted seven-point checklist correctly, and arrange urgent specialist assessment without unsafe destructive sampling.

  • ABCDE prompts asymmetry, border irregularity, colour variation, diameter and evolution; evolution is often the most useful single feature.
  • The ugly-duckling sign identifies a lesion that differs from the person’s background naevus pattern, even if it does not satisfy every ABCDE letter.
  • Nodular melanoma may be symmetrical, uniformly coloured and initially small; use elevated, firm and growing over weeks to months as an additional warning pattern.
  • NICE weighted seven-point major features—change in size, irregular shape and irregular colour—score 2 each; minor features score 1 each.
  • Minor features are diameter 7 mm or more, inflammation, oozing and change in sensation; a total of 3 or more triggers urgent suspected-melanoma referral.
  • Examine all skin, including scalp, nails, palms and soles, with informed consent and a chaperone where preferred; do not assume low risk from skin tone.
  • Dermoscopy by a trained clinician improves diagnostic accuracy but does not make a changing suspicious lesion safe for routine review.
  • Do not curette, cauterise, freeze or partially sample a possible melanoma in primary care; urgent specialist full-thickness excision planning preserves staging.

Key red flags

Evolution, an ugly-duckling lesion, nodular growth, bleeding, ulceration, irregular colour or shape, nail-unit pigment extending onto skin, or a weighted seven-point score of 3 or more requires urgent suspected-cancer referral.

Nodular growth

A new elevated, firm and continuously growing papule or nodule over weeks to months can be melanoma without classic ABCD asymmetry.

Acral or nail warning

An enlarging irregular palm or sole macule, broad changing nail band, nail dystrophy or pigment on adjacent skin requires urgent specialist review.

Investigation priorities

01
Weighted seven-point checklistFirst step

Standardise urgent-referral assessment of a suspicious pigmented lesion.

Management branches

Suspicious pigmented lesionRefer on pattern and evolution

The weighted checklist scores 3 or more, dermoscopy suggests melanoma, or an ugly-duckling, nodular, acral or nail warning exists.

  1. Document history, measurements, morphology, patient’s comparison pattern and relevant risk factors without attempting destructive treatment.
  2. Make an urgent suspected-cancer referral using the local pathway and attach consented images only when secure systems and policy allow.
  3. Explain referral urgency without declaring a diagnosis, safety-net further growth or bleeding and ensure the patient knows how the appointment will arrive.
Open full textbook →Answer 2 questions
Sources and review status3 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Apply principles in context and verify current guidance when a decision affects care. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE NG12 suspected skin cancer recommendationsWeighted checklist and urgent melanoma, SCC and BCC referral.
  • NICE NG14 melanoma assessment and managementDermoscopy, photography, biopsy and specialist assessment.
  • NHS melanoma skin cancerClinical warning features, diagnosis, treatment and follow-up.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom